Global Open Innovation, from Science to business partnering
The Embassy of the Republic of Korea to the Kingdom of Belgium and Mission to the European Union and Korea Trade-Investment Promotion Agency in Brussels (KOTRA) is delighted to invite you to the Belgium-Korea Pharma-Bio Conference on the 8th November 2018 at Le Châtelain Brussels Hotel.
This seminar is an opportunity to get a deeper insight into Korean pharmaceutical and bio industry following the success of last year’s event, “The Pharmaceutical Industry: Opportunities for further EU-Korea Cooperation”.
Furthermore, the conference seeks to provide a platform for further interaction with Korean pharmaceutical-bio companies and favour partnerships in various fields from R&D to pipeline development including clinical trials and investments.
For decades, Belgium has been a key country in the development of the global pharma-bio sector, while Korea has become a frontrunner in emerging industries. Indeed, successful partnerships with major Belgian companies have contributed to the creation of innovative and sustainable business in the Korean pharmaceutical sector.
Moderated by Dr Namshik HAN, Group Leader of the Computational Biology Group at the Milner Therapeutics Institute University of Cambridge, representatives from the South Korean Ministry of Health and Welfare, the Belgian Federal Agency for Medicines and Health Products and also from the South Korean and Belgian pharmaceutical industry representatives, will provide an overview of the policies and their developments in both countries, while highlighting the opportunities for growth and cooperation.
The seminar followed by the B2B networking programme is a unique opportunity both to favour new partnerships as well as to expand existing cooperation by gaining deeper knowledge into the Korean pharmaceutical and bio business ecosystem and its latest trends.
Ambassador of the Republic of Korea to the Kingdom of Belgium and to the European Union
Ministry of Health and Welfare of the Republic of Korea
Belgium’s Federal Agency for Medicines and Health Products (FAMHP) – to confirm
Korea Pharmaceutical and Bio-Pharma Manufacturers Association